Acute liver injury and Viagra: reported cases

Although hepatotoxicity caused by sildenafil is considered rare in the literature, there have been at least five reported cases of acute liver injury attributed to its use. However, no instances of acute hepatic failure have been reported in association with sildenafil.

Latency period and intermittent use of Sildenafil

The latency period in most reports of acute liver injury related to sildenafil has been unclear, partly due to the intermittent and sometimes unacknowledged use of the drug. However, it appears that the latency period ranges from 1 to 8 weeks.

Hepatotoxicity of Sildenafil: rarity and uncertainty

Despite the few cases of acute liver injury linked to sildenafil use, the hepatotoxicity of the drug is not completely convincing and must be quite rare, if it occurs at all.

The connection between sildenafil and liver damage remains uncertain.

Sildenafil's effect on hematopoietic function in rats with induced cirrhosis

In a study conducted on rats with experimentally induced cirrhosis, it was found that sildenafil might have significantly affected the hematopoietic function of the liver. However, it is important to note that these results were observed in rats and may not directly translate to humans.

Liver function alterations due to subchronic exposure to Sildenafil overdoses

Another study reported significant alterations in liver functions as a result of subchronic exposure to sildenafil overdoses. This suggests that high doses of sildenafil might have negative effects on liver function, although further research is needed to confirm this hypothesis.

Sildenafil's impact on splanchnic blood flow, oxygen consumption, and hepatic venous pressure gradient in patients with cirrhosis

A study investigating the effects of sildenafil on patients with cirrhosis found that the drug did not induce any profound clinically relevant changes in splanchnic blood flow, oxygen consumption, and hepatic venous pressure gradient. This indicates that sildenafil may not have a significant impact on liver function in patients with cirrhosis.

Precautions and consultation for patients with liver disease or cirrhosis

Sildenafil is generally well-tolerated and safe in patients with non-alcoholic fatty liver disease (NAFLD). However, its effectiveness may be reduced in individuals with comorbidities. Patients with liver disease or cirrhosis should exercise caution and consult their healthcare provider before taking sildenafil, as the effects of the drug may be increased due to slower removal from the body.

Assessing the potential risks and benefits of Sildenafil use in patients with liver disease or cirrhosis

In conclusion, while there have been some reports of acute liver injury associated with sildenafil use, the hepatotoxicity of sildenafil is not completely convincing and must be quite rare, if it occurs at all. Patients with liver disease or cirrhosis should consult their healthcare provider to discuss the potential risks and benefits of using sildenafil.